Influenza Vaccine Market Outlook:
Influenza Vaccine Market size was valued at USD 10.7 billion in 2024 and is set to exceed USD 24.9 billion by the end of 2037, registering over 6.9% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of influenza vaccine is estimated at USD 11.8 billion.
The growing demand for influenza vaccine accelerated with the global patient pool capacity of over 1 billion annually. As per the reporting of the World Health Organization, the U.S. government allocates approximately USD 3.9 billion every year for the influenza vaccine distribution. Influenza vaccines have segmented demand, for instance, geriatric, pediatric, and immunocompromised populations. Advancements of vaccines to cell-based leverage the patient outcome and enable a market surge through it. The majority of the government-initiated programs are conducted through egg-based vaccines that often face supply chain constraints due to the limitation in manufacturing scalability.
API is one of the raw materials required for the production of influenza vaccines, and the supply chain is dependent on the markets of the U.S., EU, and India. A complex supply chain management is experienced due to approximately 7 months of lead time, and the glass shortage trend in the global market has raised the cost of manufacturing. As per the data of the U.S. Bureau of Labor Statistics, the producer price index rose by 4.4% and the consumer price index increased by 3.3% in 2024.
